ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells
Abstract Management of infection with hepatitis B virus (HBV) remains a global health problem. Persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is responsible for modest curative efficacy of currently licensed drugs. Novel gene editing technologies, such as those...
Main Authors: | Tristan Scott, Buhle Moyo, Samantha Nicholson, Mohube Betty Maepa, Koichi Watashi, Abdullah Ely, Marc S. Weinberg, Patrick Arbuthnot |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-07642-6 |
Similar Items
-
Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs
by: Mohube Betty Maepa, et al.
Published: (2017-06-01) -
Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?
by: Kristie Bloom, et al.
Published: (2018-04-01) -
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
by: Fiona van den Berg, et al.
Published: (2020-08-01) -
Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters
by: Kun Yan, et al.
Published: (2021-06-01) -
Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter
by: Mohube Betty Mowa, et al.
Published: (2014-01-01)